SOSV is a global venture capital firm headquartered in Princeton, New Jersey, focused on seed-to-growth investments in deep tech, life sciences, hardware and software, with a strong emphasis on human and planetary health. The company operates startup development programs such as HAX and IndieBio, offering facilities, labs, engineering resources, mentorship, and collaborative workspaces to help founders advance technology and accelerate fundraising. Beyond capital, SOSV provides hands-on support to accelerate product development, customer acquisition and scaling, connecting portfolio companies with a global network of partners and investors. Its ecosystem spans multiple regions and markets, including cross-border ventures in Asia, and it maintains a portfolio of startups that have progressed to subsequent funding rounds. In addition to direct investments, SOSV’s programs and resources are designed to help early-stage companies mature toward scalable, sustainable growth while fostering innovation across sectors that address health, climate, and technology challenges.

OrbiMed is a global healthcare investment firm founded in 1989 and based in New York, with a worldwide presence that includes offices in several regions. It allocates capital across private equity, venture capital, and public equity to support healthcare companies at various stages, from startups to established firms. Its focus spans biopharmaceuticals, medical devices, diagnostics, life sciences tools, and digital health, as well as healthcare services. The firm pursues opportunities across major markets in North America, Europe, and Asia, often leveraging region-specific teams to invest in companies in Israel, China, India, South Korea, and other jurisdictions. OrbiMed emphasizes building world-class companies by providing strategic financing, industry expertise, and global resources to portfolio companies in pursuit of medical breakthroughs and sustainable growth.

RA Capital Management is a Boston-based investment management firm specializing in growth-oriented and early-stage support for healthcare, life sciences, and planetary health companies. The company deploys capital across private seed rounds, series financings, and public markets, with a focus on drugs, medical devices, diagnostics, and tools that advance patient care. It leverages a science-driven approach through its research platform TechAtlas and provides value-added services such as board representation, executive recruitment, and market intelligence to portfolio companies. The firm operates an incubator program called Raven to nurture biomedical innovation and maintains an Innovator Resources program to guide company development. RA Capital emphasizes evidence-based investing, long-term partnerships, and social responsibility, aiming to drive value creation from inception through commercialization.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore. It backs early and growth-stage technology, consumer and healthcare companies, applying deep industry knowledge and hands-on support to help portfolio companies scale. The firm manages US-dollar and RMB funds and maintains a global footprint, including a dedicated US arm, Qiming Venture Partners USA, to pursue cross-border opportunities in healthcare, therapeutics and digital health. Since inception, it has invested in more than 530 companies and achieved more than 200 exits via IPOs, M&A or other means, with over 70 portfolio companies reaching unicorn or super unicorn status. Qiming emphasizes long-term partnerships with entrepreneurs, aligning resources and networks to drive innovation and societal progress across its portfolio.

Eli Lilly and Company is a global pharmaceutical company engaged in discovery, development, manufacture, and sale of medicines. It operates with facilities in the United States, Puerto Rico, and numerous other countries, and its products are sold in about 135 countries. The company conducts research to address human diseases and also pursues animal health research and products to support animal health and agricultural production. Lilly emphasizes patient support, safety, and quality manufacturing, and pursues ongoing innovation in areas such as neuroscience, cardiometabolic disease, cancer, and immunology to bring new therapies to patients worldwide.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for chronic diseases, with insulin and diabetes care at its core. It develops and distributes insulin and other diabetes therapies, and invests heavily in scientific research and biotechnology to advance breakthroughs. The company operates worldwide, aiming to expand access to its treatments and improve patient outcomes, while emphasizing sustainability, partnerships, and social responsibility.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, founded in 2013. It connects accredited individual investors—especially alumni from top entrepreneurial schools—to venture opportunities by pooling investments and backing companies with alumni connections alongside institutional lead investors. The firm offers diversified portfolios through focused funds, syndicates, and investing clubs, enabling access to venture deals across sectors, stages, and geographies. It emphasizes transparency, due diligence, and co-investment with established venture capital firms.

General Catalyst is a venture capital firm that provides early-stage and growth equity investments in technology companies. Founded in 2000 and based in the United States, the firm backs startups across consumer, enterprise software, fintech, crypto, and health technologies, offering mentorship and strategic guidance to help ideas scale. It participates in seed and growth rounds, often taking minority or majority stakes, and supports portfolio companies with resources and networks across North America and Europe.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Deerfield Management is a New York-based healthcare investment firm founded in 1994. It pursues long-term investments across therapeutics, medical devices, diagnostics, digital health, and healthcare services, managing a diverse portfolio of private and public investments. The firm combines investment activity with information gathering and philanthropy, leveraging Deerfield Intelligence, market research, and data-driven insights to inform decisions. It operates initiatives such as Deerfield Discovery and Development and supports charitable work through the Deerfield Foundation, focusing on improving children’s health worldwide. Through its strategy of connecting capital, ideas, and technology, Deerfield Management seeks to advance human health by supporting innovation across the healthcare ecosystem.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, founded in 1996. It invests in technology and life sciences companies across the United States and Europe, supporting multiple stages from early development to growth. Its portfolio spans software, healthcare information technology, digital health, biotechnology, pharmaceuticals, and related life sciences, with emphasis on molecules, platforms, therapeutics, genomics, and data-driven healthcare solutions. The firm maintains a presence in Boston and San Francisco and emphasizes deep engagement with founders, offering strategic guidance and network resources to accelerate growth.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, including pharmaceuticals, biotechnology, medical devices, and life sciences. Versant combines investment, operating, and scientific expertise to support portfolio companies through strategic guidance and hands-on involvement in company building. The firm manages substantial capital, enabling a hands-on approach to helping entrepreneurs build durable companies addressing high unmet medical needs.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

ARCH Venture Partners is a Chicago-based venture capital firm that backs science-driven startups across life sciences, biotechnology, health tech, and related technologies. Founded in 1986, the firm emphasizes innovations developed in academic research institutions and national laboratories, providing long-term, hands-on support from inception through scalable growth. ARCH targets companies co-founded by scientists and entrepreneurs, seeks to accelerate medical and technological breakthroughs, and aims to translate research into commercial products. The firm invests across stages, often from early rounds to later-stage financing, and collaborates with a broad mix of corporate, financial, and private investors. ARCH operates with a national and international reach, funding companies in the United States and beyond, with a focus on disruptive science aimed at preventing, detecting, and treating diseases.

Antler is a global venture capital firm based in Singapore that backs early-stage technology companies. It runs incubation programs and provides a global community of co-founders, access to talent, expert advisors, expansion support, and capital to help startups grow. The firm targets a broad range of sectors, including healthcare, finance, software, energy, consumer and B2B technologies, and operates through regional programs across Europe, the United States, the United Kingdom, Southeast Asia, India, Africa, and beyond.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. Based in Palo Alto, California, with offices in New York City, it specializes in seed and early-stage investments across technology and healthcare, including information technology, software, cybersecurity, genomics, and digital health. The firm supports entrepreneurs with capital, strategic guidance, and access to its network to help build enduring companies. Notable portfolio entries include Apple, Illumina, Gilead Sciences, Intel, Nest, Endeca, and SlideShare, reflecting a history of backing influential technology and life sciences ventures.

High-Tech Gründerfonds is a Germany-based venture capital firm that provides seed and early-stage financing to technology-focused startups. Founded in 2005, it operates as a public-private partnership with government and corporate investors to support German and European tech companies across digital technology, industrial tech, life sciences, chemistry and related areas. The firm offers capital and expertise to help startups move from concept to market, typically engaging in initial rounds and follow-on funding to accelerate growth. Since inception it has backed hundreds of startups and supported follow-on rounds, helping to stimulate innovation and entrepreneurship in Germany.

Invus is a private investment firm founded in 1985 and based in New York with a global footprint. It partners with entrepreneurs and owner-managers to drive transformative growth through flexible, long-term capital and customized investment approaches. The firm aligns its incentives with management and pursues opportunities across private equity and selective co-investments, leveraging an evergreen capital base to support portfolio companies through bumps and cycles. Invus operates globally with offices in New York, London, Paris, and Hong Kong and focuses on companies with competitive advantages in consumer, technology, and life sciences sectors, among others.

F-Prime Capital is a venture capital firm founded in 1969 and based in Cambridge, Massachusetts. It invests globally in sectors including crypto, enterprise information technology, fintech, frontier tech, health information technology and services, medtech, and therapeutics, as well as broader technology companies. The firm maintains lean, entrepreneurially oriented teams in the United States and Europe and supports founders with domain expertise and industry relationships to help build meaningful, scalable businesses. With a history of backing notable technology and life sciences entrepreneurs, F-Prime Capital focuses on helping early-stage companies achieve breakthrough growth while maintaining a long-term, collaborative partnership with portfolio teams.

Right Side Capital Management is a San Francisco-based venture capital firm founded in 2010 that invests in early-stage technology startups. It specializes in pre-seed and seed rounds for capital-efficient companies, with a focus on the United States and Canada and occasional activity in Western Europe, Israel, Australia, and New Zealand. The firm typically makes 75 to 100 investments per year, with round sizes from 50,000 to 500,000 and pre-money valuations ranging from 1,000,000 to 3,500,000. Portfolio companies are typically located outside the San Francisco Bay Area and New York City, and the firm aims to provide a clear yes or no on opportunities within about two weeks.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that invests in biotechnology and healthcare companies across the United States. The firm supports biotech ventures by providing capital and strategic guidance to help advance innovative therapies and discoveries. It operates as a registered investment adviser, offering investment advisory services to entrepreneurs and venture teams as they work to bring new biotech solutions to market.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a nonprofit organization founded in 1982 that strengthens the Philadelphia region's technology ecosystem by providing capital, strategic guidance, and professional connections to technology startups and growth companies across Philadelphia, Bucks, Delaware, Chester, and Montgomery counties. It serves as a seed-stage capital provider and investor across information technology, health, and physical sciences, advancing technology commercialization through university–industry partnerships and regional initiatives. The organization aims to accelerate innovation, create jobs, and build a robust entrepreneurial community by offering funding, mentorship, and access to a broad network of resources.

StartUp Health is a global organization and community founded in 2011 that unites health startups, scaleups, funders, thought leaders, and policymakers to accelerate healthcare innovation. It operates a network and programs called Health Moonshot Communities, supports more than 330 companies across six continents and 26 countries, and provides members with access to a network, programs, media content, and events to advance digital health, biotech, and life sciences solutions. The organization aims to improve health outcomes by fostering collaboration, strategic growth, and the pursuit of ambitious health moonshots such as improving access to care, curing disease, ending cancer, and advancing women's and children's health.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Redmile Group is a San Francisco-based private equity firm with an office in New York that focuses on investments in the healthcare sector, pursuing opportunities across venture, growth, and crossover stages to support healthcare companies with strategic capital and partnerships.

Vivo Capital is a global healthcare investment firm founded in 1996 and based in Palo Alto, California, with offices in Asia. It operates a multi-fund platform spanning growth equity, private equity including buyouts, venture capital, and public equity, and invests broadly in biotechnology, pharmaceuticals, medical devices, and healthcare services across major markets. The firm pursues opportunities worldwide, supporting companies at various development stages with a team of physicians, scientists, entrepreneurs, operating executives, and industry experts who contribute deep sector insight. It manages approximately $5.8 billion in assets under management.

Andreessen Horowitz is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, and headquartered in Menlo Park, California. The firm backs technology companies across stages from seed to growth, with a focus on software, back-end infrastructure, cloud computing, enterprise software and services, and consumer internet and fintech, often investing at the intersection of computer science and other industries; it supports portfolio companies with capital and resources to drive innovation and scale.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio of prescription drugs and vaccines, with notable products such as Prevnar 13, Ibrance, and Eliquis. The company serves customers worldwide, with substantial international and emerging-market sales. Through ongoing research and development, Pfizer pursues new treatments to address major diseases, including cancer and neurodegenerative conditions, and aims to improve patient outcomes by delivering safe, effective, and accessible therapies. Founded in 1849 and headquartered in the United States, Pfizer operates globally to advance health care through science, partnerships, and scalable manufacturing capabilities.

Gaingels is a venture capital organization focused on supporting LGBTQ+ founders and leaders and their allies. It invests across stages and industries, building a global portfolio of 130+ companies and deploying around $70 million in capital. Beyond funding, Gaingels helps portfolio companies recruit diverse C-suite and board talent and fosters a global community of investors, operators, and entrepreneurs working toward inclusive leadership and positive social change through business.

Mission BioCapital is a life science venture capital firm focused on funding early-stage biotechnology and related life sciences companies. Based in Cambridge, Massachusetts, the firm has a long history of collaborating with portfolio companies and supporting entrepreneurs beyond capital, offering mentorship, strategic guidance, and access to laboratory space in the United States and Europe. Since 2009, it has operated multiple funds, including a fifth fund, and runs programs such as a Platinum Program that provides early-stage funding up to 500,000 and practical support in areas such as drug discovery, legal, accounting, and scientific mentorship to accelerate development from concept to clinical milestones.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across development stages, from early discovery to later-stage growth. It backs therapeutics, diagnostics, health technology, and digital health ventures in Europe, leveraging ties with research centers and hospitals to translate scientific advances into clinical and commercial success. The firm operates with a Europe-wide reach, with a notable presence in France, and emphasizes collaborating with researchers and entrepreneurs to support impactful, sustainable healthcare solutions.

SV Health Investors is a global healthcare-focused private equity and venture capital firm that backs therapeutics, biotech, medtech, and other life sciences opportunities across the United States and Europe. Founded in 1993 and headquartered in Boston, with offices in San Francisco and London, the firm supports investments across development stages and seeks to build breakthrough medicines, devices, and related technologies. With a multi-decade track record, SV Health Investors aims to create value for patients and investors through strategic partnerships, growth-led funding, and successful exits.

Lightspeed Venture Partners is a global venture capital firm based in Menlo Park, California, with additional offices in Beijing, Shanghai, New Delhi, and Herzliya. Founded in 2000, the firm backs companies across seed, early, and growth stages, investing in software, enterprise technology, consumer internet, fintech, healthtech, and cleantech sectors. It provides equity and debt financing and seeks opportunities globally, including the United States, Asia, and Israel. Lightspeed partners with entrepreneurs to scale businesses from inception through expansion, supporting a broad range of sectors such as AI, mobile, e-commerce, data infrastructure, and security. The firm emphasizes long-term partnerships and hands-on involvement to help portfolio companies navigate growth and market dynamics.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health, and the bioeconomy, supporting companies from preclinical stages to growth, across Europe and North America. With two decades of experience, Forbion combines venture funding with active company building and expansion support, while integrating ESG principles to drive responsible, impactful growth.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

Keiretsu Forum is a global investment community consisting of accredited private equity investors, venture capitalists and corporate/institutional investors. Established in 2000, it operates through chapters around the world and facilitates selective investment opportunities by connecting members with emerging companies across technology, healthcare, consumer products and other growth sectors. The organization focuses on private equity funding, deal flow and access to capital, supporting entrepreneurs through curated presentations and mentoring while enabling investors to participate in opportunities aligned with their investment criteria. Keiretsu Forum seeks to create value for members and portfolio companies by leveraging a network of resources, partners and forums to foster high-quality investments and cross-border collaboration.

Atlas Venture is a Cambridge, Massachusetts-based biotech venture capital firm with a 30-year track record of building breakthrough companies in life sciences. It concentrates on translating innovative biology into medicines through early-stage, seed-led venture creation and investments in life sciences and technology startups. The firm typically serves as a lead investor and seeks board representation to help guide portfolio companies, aiming to build scalable businesses and realize value. Atlas Venture has supported the development of multiple medicines and launched startups through its incubator program, reflecting its emphasis on scientific translation and entrepreneurship.

Samsung Electronics is a global technology company headquartered in South Korea that designs, manufactures, and sells a broad range of electronics and information technology products. The company operates in consumer electronics, mobile communications, IT, and device solutions, offering smartphones, tablets, TVs, home appliances, PCs, memory and storage products, and other electronic components. It is a leading producer of semiconductors and display technologies and supplies components for its own devices as well as external customers. Samsung Electronics maintains a worldwide presence across regions including Korea, North America, Europe, and the Asia-Pacific, supports repair and service for its products, and invests in research and development to advance advanced materials, processing, and new architectures. It is widely regarded as the largest smartphone and television manufacturer in the world, underpinning a broad ecosystem of devices and technologies.

FJ Labs is a New York-based venture capital firm focused on marketplaces and consumer-facing startups. Founded in 2015 by Fabrice Grinda, the firm is stage-agnostic, prioritizing seed and Series A investments in scalable businesses with strong unit economics and potential to become market leaders. Typical checks run from fifty thousand to five million dollars. FJ Labs leverages a broad network to support portfolio companies in fundraising and growth and frequently co-invests with other global funds to amplify impact. The firm emphasizes rapid decision-making to speed deployment and pursues opportunities in large economies with mature venture ecosystems.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

Based in Seoul, Korea Investment Partners is a leading venture capital and private equity firm with a global footprint, including offices in Shanghai, Beijing, and Sunnyvale. With over 30 years of investment experience, it provides capital and growth funding to bold entrepreneurs across technology, media, healthcare, and manufacturing, backing notable companies such as Kakao, Naver, YG Entertainment, Osstem Implant, Bodyfriend, DoubleU Games, and Didi Chuxing. The firm manages multiple funds with assets under management in the billions and operates a global network to support portfolio companies from early to growth stages. It is a subsidiary of Korea Investment Holdings, aligning client interests with governance and long-term value creation.

HealthTech Capital is a membership-based angel investor network and mentoring program founded in 2010 and based in Los Altos Hills, California. It connects accredited angel investors with early-stage health technology and medical technology startups, healthcare systems, venture and corporate partners, and clinical providers to foster deal flow and collaboration. The organization supports portfolio companies through mentoring, networking initiatives, and access to its broad network across the United States and Asia, with activities that combine funding and guidance to accelerate the development of innovative healthcare technologies at the intersection of healthcare, technology and mobility.

Founders Fund is a San Francisco-based venture capital firm that invests across seed to growth stages in science and technology companies addressing difficult problems. The firm backs ventures across sectors such as aerospace, artificial intelligence, advanced computing, energy, health, consumer Internet, software, and related technologies, seeking transformative impact. It maintains a founder-friendly approach that emphasizes strong support with minimal interference. Founders Fund has backed notable companies including SpaceX, Palantir, Facebook, and Airbnb, and pursues a global investment footprint across the United States and beyond.

8VC is a San Francisco-based technology and life sciences investment firm that partners with founders to develop transformative technologies and create long-term economic and societal value. The firm pursues investments across sectors including healthcare, energy, consumer goods, financial services, information technology, manufacturing, enterprise software, logistics, and cybersecurity, and across stages from seed to later rounds. It emphasizes long-term partnerships and supports portfolio companies through programs such as fellowships and community-building efforts that foster collaboration and growth. 8VC seeks to back companies leveraging breakthrough technologies to address critical challenges and drive innovation, aiming to generate durable value for founders and stakeholders.

European Investment Fund is the European Union’s financing arm for small and medium-sized enterprises and mid-caps, providing financial instruments to improve access to affordable financing throughout a business lifecycle. It leverages its capital base to attract private investment through guarantees and equity funding, fostering public-private partnerships and crowding in lenders and investors to support SMEs and startups across EU member states, candidate countries, and EFTA. The EIF focuses on innovation, growth, competitiveness, social impact, and sustainability, and supports financing for sectors such as information technology, life sciences, energy, and manufacturing, helping close funding gaps and contribute to Europe’s economic resilience and strategic autonomy.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

IP Group is a global science and technology investment company focused on identifying, backing, and growing early‑stage, science‑based businesses. It commercialises intellectual property originating from research‑intensive institutions, managing the process from IP discovery to business development or the formation of strategic partnerships. The firm concentrates on HealthTech, DeepTech, and CleanTech, backing university spin‑outs and other innovative ventures with the potential to disrupt markets and deliver strong financial returns while delivering social and environmental impact aligned with the UN Sustainable Development Goals. IP Group leverages expertise in investment case development, governance, results reporting, and regulatory affairs, and cultivates collaborations with leading research institutions to accelerate growth. As a catalyst for innovation, it provides capital, strategic guidance, and operational support to portfolio companies to translate scientific advances into scalable technologies that benefit society and the economy.